Are You in Control of Your Data

Bayer Enhances Sensitivity of Automated Immunoassay for Hepatitis B and HIV

Bayer ADVIA Assays

Bayer Diagnostics (a division of Bayer HealthCare) has increased the sensitivity of its automated HBc Total and HIV 1/O/2 assays for use on the ADVIA Centaur® Immunoassay System to improve laboratories' detection capability for Hepatitis B and Human Immunodeficiency Virus (HIV) infections.

The HBc Total assay indicates whether a patient has been exposed to or infected by the Hepatitis B virus which can lead to chronic liver disease, cirrhosis or primary liver cancer. The HIV 1/O/2 assay is used to detect infection by various strains of the HIV virus (HIV-1, HIV-1 Group O and HIV-2) which are associated with the development of acquired immunodeficiency syndrome (AIDS).

A revised cut-off point of 0.5 Index has been set for the new HBc Total assay, eliminating the 'equivocal zone' in which results might be subject to varying interpretation when using the previous method. Analytical capacity has been improved from 0.5 - 0.6 PEI IU to 0.2 PEI IU at the cut-off. 100% clinical sensitivity and 99.75% clinical specificity have been established in EU clinical trials, making the assay suitable for the detection of both acute and chronic Hepatitis B infections.

The HIV 1/O/2 assay has been enhanced to increase its sensitivity to HIV-1 group O and HIV-2 in patient samples, reducing the risk of false negative reactions.

Both these enhanced assays can be run in random access mode alongside all other analytes on the high-throughput ADVIA Centaur® Immunoassay System, allowing laboratories to deliver a rapid testing service with absolute confidence in the accuracy of results.


NOTE: This item is from our 'historic' database and may contain information which is not up to date.

Source: Bayer Diagnostics (UK and Eire) [United Kingdom] View archived contact details
Is a subsidiary/distributor for
Siemens Medical Solutions, USA View company information

Posted: March 21, 2005
Request Information
[will open your email client]

© 2001 - 2017 Rapid Test Methods Ltd • Please join us on Twitter, Facebook and LinkedIn • RSS Feed